6576.Two
6576.TWO operates in the healthcare diagnostics industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. 6576.TWO operates in the healthcare diagnostics industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6576.TWO operates in the healthcare diagnostics industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
6576.TWO has a liquidity ratio of 3.44, indicating a strong ability to meet short-term obligations, but the company reported negative operating and free cash flows of -842,227,000 TWD and -830,516,000 TWD, respectively, suggesting potential liquidity challenges. The company's debt-to-equity ratio is 0.25, which is relatively low, indicating a conservative capital structure.
In terms of profitability, 6576.TWO reported a net loss of -883,151,000 TWD and an operating loss of -862,316,000 TWD, with a return on equity of -0.95 and a return on assets of -0.674, both of which are significantly below the industry median for profitability metrics. These figures suggest that the company is currently not generating returns that meet industry standards.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may increase the company's exposure to market-specific risks.
Looking at the growth trajectory, 6576.TWO has not provided specific numeric deltas for the current or next fiscal year, but the negative operating and free cash flows indicate a challenging growth environment. The company's recent financial performance suggests a need for strategic adjustments to improve profitability and cash flow.
The risk assessment for 6576.TWO indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to fund operations without external financing. No significant dilution sources were identified in the recent filings or transcripts.
Recent events, as disclosed in the company's filings, include a net loss and negative cash flows, which may impact investor confidence and the company's ability to fund its operations without additional financing.
- 6576.TWO has a strong liquidity position with a current ratio of 3.44, but negative operating and free cash flows indicate potential liquidity challenges.
- The company is not generating returns that meet industry standards, with a return on equity of -0.95 and a return on assets of -0.674.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- The company's net cash position is negative after accounting for total debt, which could affect its ability to fund operations without external financing.
- No significant dilution sources were identified in the recent filings or transcripts.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6576.TWO Market data — financials · 2026-05-27
- Foresee Pharmaceuticals Co Ltd Market data — analyst estimates · 2026-05-27